mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (pembrolizumab), Receives PRIME Scheme Designation from the European Medicines Agency for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection

CAMBRIDGE, MA and RAHWAY, N.J., April 6, 2023 – Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational…

Read MoremRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (pembrolizumab), Receives PRIME Scheme Designation from the European Medicines Agency for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection

Merck Ranked No. 1 in the Pharmaceutical Industry Among Barron’s 100 Most Sustainable U.S. Companies 2023

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the third consecutive year, ranking No. 1 in the pharmaceutical industry and advancing 38 spots…

Read MoreMerck Ranked No. 1 in the Pharmaceutical Industry Among Barron’s 100 Most Sustainable U.S. Companies 2023

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients…

Read MoreFDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Biologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich’s Ataxia

 Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Reata Pharmaceuticals as the sole specialty pharmacy provider for SKYCLARYSTM (omaveloxolone), the first and only treatment for Friedreich’s ataxia (FA). SKYCLARYS was approved by the…

Read MoreBiologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich’s Ataxia

McKesson ideaShare Invites Independent Community Pharmacy Teams to Annual Industry Education and Networking Event

 McKesson ideaShare in Las Vegas from June 22–25, 2023. McKesson ideaShare is the nation’s premier community pharmacy annual education and networking event, hosted by McKesson, Health Mart, and Health Mart Atlas. The event returns with double the clinical and business educational opportunities, new pharmacy…

Read MoreMcKesson ideaShare Invites Independent Community Pharmacy Teams to Annual Industry Education and Networking Event

XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today that XTANDI® (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide (Hazard Ratio [HR]:…

Read MoreXTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

 Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in…

Read MoreU.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children